Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Aging, Metabolic, Cardiovascular, and Longevity Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PAPPA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PAPPA Recombinant Protein (WT & Catalytic Mutant E483Q) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Includes inactive variant for mechanistic controls. |
View PAPPA Products |
| Substrate | IGFBP-4 Recombinant Protein Primary proteolytic substrate; required for enzymatic cleavage assays. Sequence Verified. |
View IGFBP4 Products |
| Gene Delivery | PAPPA Promise-ORF / Lentivirus Full-length ORF for stable overexpression cell lines. Endotoxin Controlled. |
View PAPPA Products |
| Benchmark Ab | Anti-PAPPA (Neutralizing Reference Clone) Recombinant positive control for assay calibration and inhibition assays. |
View PAPPA Products |
| Validator | PAPPA siRNA Set For knockdown verification and specificity controls in cell-based screening. |
View PAPPA Products |
| Related Target A | IGF1R Downstream signaling receptor; synergistic pathway for combination screening. |
View IGF1R Products |
| Related Target B | IGFBP-5 Alternative PAPPA substrate; decoy target for selectivity profiling. |
View IGFBP5 Products |
| Related Target C | PAPPA2 Homologous protease; essential for selectivity and counter-screening assays. |
View PAPPA2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Metalloprotease Activity Preservation | HEK293 Expressed PAPPA with Native Glycosylation; >95% Purity by SEC-HPLC |
| Substrate Specificity (IGFBP-4 vs IGFBP-5) | Sequence Verified IGFBP-4 and IGFBP-5 Orthologs (Human/Mouse/Cyno) |
| Off-target Liability (ADAM Family & PAPPA2) | Homolog Panel Available: ADAM12, ADAM28, PAPPA2 for Counter-screening |
| Cross-species Translation (Aging Models) | Human and Mouse PAPPA with >95% Sequence Verified Identity |
| Need for Catalytically Dead Control | WT + E483Q mutant pair available; sequence verified by mass spec |
| False Positives in Endogenous Assays | Target-specific validated siRNA included for robust specificity checks |
Live PAPPA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PAPPA therapeutics is intensifying, with major players shifting focus from diagnostic biomarker applications (such as acute coronary syndrome and prenatal screening) to therapeutic metalloprotease inhibition targeting the IGF axis. As an upstream regulator of IGF signaling, PAPPA inhibition is emerging as a powerful strategy for treating atherosclerosis, renal fibrosis, and age-related metabolic decline. As first-generation antibody and small molecule inhibitors enter preclinical development, the next wave of R&D is targeting combination approaches with senolytics, IGF1R inhibitors, and metabolic regulators.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Neutralizing) | Longevity Biotechs, Academic Labs, Early-stage Biotechs | Aging, Senescence, Metabolic Syndrome, Atherosclerosis, Renal Disease | Protease Activity Inhibition (Need active PAPPA + IGFBP-4 substrate) |
| Small Molecule Inhibitor | Metabolic Disease Focused Pharma, Preclinical Pharms | Type 2 Diabetes, Cancer, Metabolic Disorders, Anti-aging | Enzymatic Selectivity Panel (Need ADAM family & PAPPA2 orthologs) |
| Biologic (Exosite Blocker) | Emerging Biotech | Cardiovascular Disease | Binding Kinetics (Need high-purity PAPPA for SPR) |
| Gene Therapy / AAV | Longevity Startups, Academic Translational Labs | Age-related muscle atrophy, Rare growth deficiencies | Expression Validation (Need specific benchmark Abs & ORF Lentivirus) |